Mani Foroohar
Stock Analyst at Leerink Partners
(1.98)
# 3,117
Out of 5,132 analysts
168
Total ratings
50.54%
Success rate
-0.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Outperform | $16 → $20 | $7.99 | +150.31% | 11 | Dec 15, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $85 → $100 | $80.63 | +24.02% | 16 | Dec 15, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $75 → $86 | $75.25 | +14.29% | 16 | Dec 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $370 → $351 | $314.40 | +11.64% | 12 | Dec 15, 2025 | |
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $42.23 | -57.38% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $6.31 | +216.96% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.27 | +114.07% | 13 | Oct 3, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $17.79 | -43.79% | 2 | Jul 21, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $3.49 | +71.92% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $9.35 | +188.77% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $72 | $17.37 | +314.51% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $3.85 | +341.56% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $103.10 | -52.47% | 11 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $12.68 | +73.50% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $10.40 | +25.00% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $11.40 | +154.39% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $9.78 | +216.97% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.66 | +960.61% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $63.82 | -37.32% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $11.87 | +607.67% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $1.76 | +297.73% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $27.92 | +175.79% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.00 | +20.00% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $53.07 | +43.21% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.58 | +2,051.90% | 4 | May 12, 2022 |
REGENXBIO
Dec 15, 2025
Maintains: Outperform
Price Target: $16 → $20
Current: $7.99
Upside: +150.31%
Ionis Pharmaceuticals
Dec 15, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $80.63
Upside: +24.02%
BridgeBio Pharma
Dec 15, 2025
Maintains: Outperform
Price Target: $75 → $86
Current: $75.25
Upside: +14.29%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintains: Market Perform
Price Target: $370 → $351
Current: $314.40
Upside: +11.64%
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $42.23
Upside: -57.38%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $6.31
Upside: +216.96%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.27
Upside: +114.07%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $17.79
Upside: -43.79%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $3.49
Upside: +71.92%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $9.35
Upside: +188.77%
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $17.37
Upside: +314.51%
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $3.85
Upside: +341.56%
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $103.10
Upside: -52.47%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $12.68
Upside: +73.50%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $10.40
Upside: +25.00%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $11.40
Upside: +154.39%
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $9.78
Upside: +216.97%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.66
Upside: +960.61%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $63.82
Upside: -37.32%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $11.87
Upside: +607.67%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $1.76
Upside: +297.73%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $27.92
Upside: +175.79%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.00
Upside: +20.00%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $53.07
Upside: +43.21%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.58
Upside: +2,051.90%